Buffington Mohr McNeal trimmed its holdings in Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 4.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,050 shares of the company’s stock after selling 250 shares during the period. Buffington Mohr McNeal’s holdings in Henry Schein were worth $368,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Summit Securities Group LLC bought a new stake in Henry Schein during the second quarter worth $31,000. Beach Investment Counsel Inc. PA bought a new stake in shares of Henry Schein in the 2nd quarter worth $37,000. Blue Trust Inc. grew its stake in shares of Henry Schein by 104.2% in the 2nd quarter. Blue Trust Inc. now owns 931 shares of the company’s stock worth $60,000 after acquiring an additional 475 shares in the last quarter. Mather Group LLC. bought a new position in shares of Henry Schein during the first quarter valued at about $97,000. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its position in shares of Henry Schein by 282.1% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,490 shares of the company’s stock valued at $109,000 after purchasing an additional 1,100 shares in the last quarter. 96.62% of the stock is owned by institutional investors.
Henry Schein Price Performance
Shares of NASDAQ:HSIC opened at $71.67 on Friday. The firm has a market capitalization of $9.18 billion, a PE ratio of 24.21, a P/E/G ratio of 1.98 and a beta of 0.86. The company has a quick ratio of 0.90, a current ratio of 1.55 and a debt-to-equity ratio of 0.46. The company has a 50-day moving average price of $70.26 and a two-hundred day moving average price of $69.90. Henry Schein, Inc. has a twelve month low of $60.01 and a twelve month high of $82.63.
Wall Street Analyst Weigh In
Several research firms have commented on HSIC. Robert W. Baird decreased their price objective on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. JPMorgan Chase & Co. decreased their price target on Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Barrington Research reissued an “outperform” rating and issued a $82.00 price objective on shares of Henry Schein in a research report on Friday, September 20th. Evercore ISI upped their price objective on Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research note on Tuesday, October 8th. Finally, UBS Group lowered their target price on Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Henry Schein currently has an average rating of “Hold” and an average target price of $77.50.
Check Out Our Latest Report on Henry Schein
Insider Activity
In related news, SVP Lorelei Mcglynn sold 21,035 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the sale, the senior vice president now owns 71,833 shares of the company’s stock, valued at approximately $4,978,026.90. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.14% of the stock is owned by company insiders.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Articles
- Five stocks we like better than Henry Schein
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Stock Market Sectors: What Are They and How Many Are There?Â
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC – Free Report).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.